NCT03003676View on ClinicalTrials.gov

A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

July 31, 2020

Study Completion Date

October 31, 2020

Conditions
Advanced or Unresectable Melanoma Progressing After PD1 Blockade
Interventions
BIOLOGICAL

ONCOS-102

Engineered oncolytic adenovirus expressing Granulocyte-macrophage colony stimulating factor (GM-CSF)

DRUG

Cyclophosphamide

Pre-treatment

DRUG

Pembrolizumab

PD1 blockade

Trial Locations (4)

Unknown

University of Maryland Comprehensive Cancer Center, Baltimore

Memorial Sloan Kettering Cancer Center, New York

Fox Chase Cancer Center, Philadelphia

Oslo University Hospital - The Norwegian Radium Hospital, Oslo

All Listed Sponsors
lead

Targovax Oy

INDUSTRY

NCT03003676 - A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade | Biotech Hunter | Biotech Hunter